TW200908964A - Use of HDAC inhibitors for the treatment of gastrointestinal cancers - Google Patents

Use of HDAC inhibitors for the treatment of gastrointestinal cancers Download PDF

Info

Publication number
TW200908964A
TW200908964A TW097116351A TW97116351A TW200908964A TW 200908964 A TW200908964 A TW 200908964A TW 097116351 A TW097116351 A TW 097116351A TW 97116351 A TW97116351 A TW 97116351A TW 200908964 A TW200908964 A TW 200908964A
Authority
TW
Taiwan
Prior art keywords
group
aryl
alkyl
heteroaryl
heterocycloalkyl
Prior art date
Application number
TW097116351A
Other languages
English (en)
Chinese (zh)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39683987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200908964(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200908964A publication Critical patent/TW200908964A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW097116351A 2007-05-04 2008-05-02 Use of HDAC inhibitors for the treatment of gastrointestinal cancers TW200908964A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91599607P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
TW200908964A true TW200908964A (en) 2009-03-01

Family

ID=39683987

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097116351A TW200908964A (en) 2007-05-04 2008-05-02 Use of HDAC inhibitors for the treatment of gastrointestinal cancers

Country Status (16)

Country Link
EP (1) EP2142190A1 (fr)
JP (1) JP2010526149A (fr)
KR (1) KR20100016171A (fr)
CN (1) CN101674825A (fr)
AU (1) AU2008247603A1 (fr)
BR (1) BRPI0811112A2 (fr)
CA (1) CA2683554A1 (fr)
CL (1) CL2008001269A1 (fr)
IL (1) IL201318A0 (fr)
MA (1) MA31356B1 (fr)
MX (1) MX2009011692A (fr)
RU (1) RU2009144842A (fr)
TN (1) TN2009000427A1 (fr)
TW (1) TW200908964A (fr)
WO (1) WO2008137630A1 (fr)
ZA (1) ZA200906739B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2005040161A1 (fr) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Hydroxamates lies au biaryle: preparation et applications pharmaceutiques
TW200530166A (en) * 2003-10-27 2005-09-16 S Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates
WO2006075165A1 (fr) * 2005-01-13 2006-07-20 Btg International Limited Combinaison de virus oncolytiques a des inhibiteurs d'angiogenese

Also Published As

Publication number Publication date
AU2008247603A1 (en) 2008-11-13
CL2008001269A1 (es) 2008-12-19
CA2683554A1 (fr) 2008-11-13
CN101674825A (zh) 2010-03-17
MX2009011692A (es) 2009-11-10
TN2009000427A1 (en) 2011-03-31
BRPI0811112A2 (pt) 2014-12-23
MA31356B1 (fr) 2010-05-03
JP2010526149A (ja) 2010-07-29
RU2009144842A (ru) 2011-06-10
WO2008137630A1 (fr) 2008-11-13
EP2142190A1 (fr) 2010-01-13
IL201318A0 (en) 2010-05-31
ZA200906739B (en) 2010-06-30
KR20100016171A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
AU2017245295A1 (en) Pharmaceutical combinations
JP2003507342A (ja) 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物
JP5665271B2 (ja) 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
RU2580609C2 (ru) Противоопухолевое терапевтическое средство
ES2896735T3 (es) Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida
JP5784274B2 (ja) Ｈｄａｃ阻害剤と代謝拮抗剤の組み合わせ
US20100144749A1 (en) Treatment of cancers with acquired resistance to kit inhibitors
US20100137398A1 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers
SK148199A3 (en) Cox-2 selective carprofen for treating pain and inflammation in dogs
JP2018532761A (ja) Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与
JP2022535406A (ja) Ｐｒｍｔ５阻害剤を使用した癌の治療法
JP2020522687A (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
JP2009532498A (ja) 有機化合物の組合せ
TW200908964A (en) Use of HDAC inhibitors for the treatment of gastrointestinal cancers
TW200904412A (en) Use of HDAC inhibitors for the treatment of bone destruction
TW589181B (en) Lymphocytic activation inhibitor and remedial agent for autoimmune disease
KR20220035143A (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
CA3178927A1 (fr) Belvarafenib a utiliser dans le traitement du cancer
TW202327594A (zh) 用ｂｅｔ溴結構域抑制劑和ｐａｒｐ抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法
JP2010515740A (ja) デアセチラーゼインヒビター製剤
JP2010526830A (ja) 黒色腫の処置のためのｈｄａｃ阻害剤の使用
US20090281159A1 (en) Use of hdac inhibitors for the treatment of lymphomas
AU3823202A (en) Cox-2 selective carprofen for treating pain and inflammation in dogs
NZ516914A (en) Compositions containing COX-2 selective carprofen and derivatives thereof for treating pain and inflammation in dogs